The purpose of this study is to measure the effect of multiple doses of orally administered povorcitinib on skin PK and to characterize plasma PK parameters of povorcitinib following multiple doses of orally administered povorcitinib.in healthy participants.

开始日期2024-08-12

申办/合作机构

Incyte Corp.

100 项与 Povorcitinib 相关的临床结果

登录后查看更多信息

100 项与 Povorcitinib 相关的转化医学

登录后查看更多信息

100 项与 Povorcitinib 相关的专利（医药）

登录后查看更多信息

项与 Povorcitinib 相关的文献（医药）

2024-06-01·JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Chronic Prurigo

Review

作者: Zeidler, Claudia ; Steinbrink, Kerstin ; Müller, Svenja ; Ständer, Sonja ; Thünemann, Julia

Summary:

Chronic prurigo (CPG) is a neuroinflammatory dermatosis characterized by prolonged pruritus lasting more than 6 weeks, pruriginous skin lesions, and repeated scratching.Patients with CPG suffer significantly from psychological distress and a marked impairment in their quality of life. The most common subtype of CPG is chronic nodular prurigo (CNPG, also called prurigo nodularis).In addition to the clinical features of CPG and the burden of disease, this CME article provides an overview of the significant advances in understanding the pathophysiology, including the associated therapeutic options for CPG. Dupilumab is the first approved therapy for moderate and severe CNPG to date from the European Medicines Agency (EMA) and the US Food & Drug Administration (FDA). It also highlights other agents currently being studied in Phase II and Phase III clinical, randomized, placebo‐controlled trials. These include biologics such as nemolizumab (anti‐IL‐31‐RA‐mAb), vixarelimab/KPL‐716 (anti‐Oncostatin‐M receptor β‐mAb), and barzolvolimab/CDX‐0159 (anti‐KIT‐mAb), as well as Janus kinase inhibitors such as povorcitinib/INCB054707 and abrocitinib, and opioid modulators such as nalbuphine.

2024-03-01·Journal of the American Academy of Dermatology

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Article

作者: Kimball, Alexa B ; Brown, Kurt ; Wang, Annie ; Porter, Martina L ; Kirby, Joslyn S ; Okun, Martin M ; Alavi, Afsaneh ; Bechara, Falk G ; Zouboulis, Christos C ; Santos, Leandro L ; Bibeau, Kristen B

BACKGROUND:

Janus kinase 1 inhibition may alleviate hidradenitis suppurativa (HS)-associated inflammation and improve symptoms.

OBJECTIVE:

To assess efficacy and safety of povorcitinib (selective oral Janus kinase 1 inhibitor) in HS.

METHODS:

This placebo-controlled phase 2 study randomized patients with HS 1:1:1:1 to receive povorcitinib 15, 45, or 75 mg or placebo for 16 weeks. Primary and key secondary end points were mean change from baseline in abscess and inflammatory nodule count and percentage of patients achieving HS Clinical Response at week 16.

RESULTS:

Of 209 patients randomized (15 mg, n = 52; 45 mg, n = 52; 75 mg, n = 53; placebo, n = 52), 83.3% completed the 16-week treatment. At week 16, povorcitinib significantly reduced abscess and inflammatory nodule count from baseline (least squares mean [SE] change: 15 mg, -5.2 [0.9], P = .0277; 45 mg, -6.9 [0.9], P = .0006; 75 mg, -6.3 [0.9], P = .0021) versus placebo (-2.5 [0.9]). More povorcitinib-treated patients achieved HS Clinical Response at week 16 (15 mg, 48.1%, P = .0445; 45 mg, 44.2%, P = .0998; 75 mg, 45.3%, P = .0829) versus placebo (28.8%). A total of 60.0% and 65.4% of povorcitinib- and placebo-treated patients had adverse events.

LIMITATIONS:

Baseline lesion counts were mildly imbalanced between groups.

CONCLUSION:

Povorcitinib demonstrated efficacy in HS, with no evidence of increased incidence of adverse events among doses.

2024-01-01·American journal of clinical dermatology

Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments

Review

作者: Zeidler, Claudia ; Müller, Svenja ; Ständer, Sonja

Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching. Patients with CPG experience a significant psychological burden and a notable impairment in their quality of life. Chronic prurigo of nodular type (CNPG; synonym: prurigo nodularis) represents the most common subtype of CPG. As CNPG is representative for all CPG subtypes, we refer in this review to both CNPG and CPG. We provide an overview of the clinical characteristics and assessment of CPG, the burden of disease and the underlying pathophysiology including associated therapeutic targets. The information provided results from a PubMed search for the latest publications and a database search for current clinical trials (ClinicalTrials.gov, EU Clinical Trials Register [European Medicines Agency]; using the following terms or combinations of terms: 'chronic prurigo', 'prurigo', 'prurigo nodularis', 'pathophysiology', 'therapy', 'biologics', 'treatment'). Dupilumab is the first authorized systemic therapy by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for CNPG to date. Topical and systemic agents that are currently under investigation in clinical randomized, placebo-controlled phase II and III trials such as biologics (e.g., nemolizumab, vixarelimab/KPL-716, barzolvolimab/CDX-0159), small molecules (ruxolitinib cream, povorcitinib/INCB054707, abrocitinib) and the opioid modulator nalbuphine are highlighted. In the last past 15 years, several milestones have been reached regarding the disease understanding of CPG such as first transcriptomic analysis, first terminology, first guideline, and first therapy approval in 2022, which contributed to improved medical care of affected patients. The broad range of identified targets, current case observations and initiated trials offers the possibility of more drug approvals in the near future.

项与 Povorcitinib 相关的新闻（医药）

2025-01-15

·Pharmaceutical Technology

JP Morgan 2025: Incyte expects period of ‘defining catalysts’

The launches reportedly represent a potential $1bn in incremental revenues for Incyte by 2029. Credit: SOPA Images / Getty Images. Incyte CEO Hervé Hoppenot has promised investors that 2025 will be “a year that will be full of many defining catalysts” for the company. Speaking at the 2025 JP Morgan Healthcare Conference, Hoppenot shared plans for the US pharma company to launch four new products in 2025, beginning with its third-line chronic graft-versus-host disease (GvHD) treatment Niktimvo (axatilimab-csfr). The drug was approved by the FDA in August 2024 and is expected to reach the US market in the first quarter of 2025. The company hopes that three other pipeline drugs will be approved in the second half of the year. These are Zynyz ( retifanlimab ) for the treatment of squamous cell anal carcinoma (SCAC), Monjuvi (tafasitamab) for follicular lymphoma, and Opzelura (ruxolitinib) cream. A supplemental NDA has been submitted for Incyte’s Opzelura cream, which has the potential to be the first topical JAK inhibitor approved for paediatric patients in the US for the treatment of atopic dermatitis (AD). Meanwhile, supplemental BLAs have been submitted for Monjuvi and Zynyz, which Incyte hopes could become the new standard of care for SCAC. The four launches reportedly represent a potential $1bn in incremental revenues for the company by 2029. Hoppenot also used the JP Morgan conference as an opportunity to highlight other anticipated milestones for Incyte this year. The company expects to announce four pivotal trial readouts, at least three Phase III study initiations and seven proof-of-concept data readouts. He highlighted three “high-impact” pipeline programmes in particular, namely povorcitinib, mCALR and CDK2 inhibitors. Oral small-molecule JAK1 inhibitor povorcitinib “is coming soon, and it could be very big”, Hoppenot said. The drug is in pivotal studies for three indications: hidradenitis suppurativa, vitiligo and prugrigo nodularis. The data for the Phase III hidradenitis suppurativa trial is expected in the first half of 2025 while vitiligo and prugrigo nodularis data is expected next year. The share price of the company increased 2.59% on 13 January, suggesting some optimism for pipeline products. Looking at the broader picture, Hoppenot explained that the business was adopting a focused, specific approach to R&D: “Our pipeline has been reduced a little bit – some projects have been stopped – and we are trying to direct our resources to what is novel biology – what is first in class or best in class.” However, he also credited diversification within the portfolio as the reason behind Incyte’s $3.1bn revenue in the first nine months of 2024, which represented a 14% year-on-year increase. Hoppenot noted that “revenue at Incyte is growing because of diversification of the portfolio and also because of international expansion”.

上市批准临床3期

2025-01-13

·Business Wire

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

WILMINGTON, Del.--( BUSINESS WIRE )--Incyte (Nasdaq:INCY) will provide an update on commercial growth, clinical progress and significant 2025 catalysts during a presentation today at 10:30 a.m. PT at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. “With significant advancements being made across our portfolio, 2025 will be a transformational year not only for Incyte, but also for the patients we serve,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “We have several novel medicines in development that can potentially address significant patient needs, and we remain on track to deliver numerous first- or best-in-class high impact launches from our pipeline by 2030.” Today’s presentation will highlight: The launch of Niktimvo™ (axatilimab-csfr) for patients living with chronic graft-versus-host disease (GVHD) and ongoing studies of axatilimab in additional indications. Near-term opportunities for tafasitamab (Monjuvi ® ) following positive results from the Phase 3 inMIND trial in patients with relapsed/refractory follicular lymphoma (FL), as well as the anticipated data evaluating tafasitamab in first line diffuse large B-cell lymphoma (DLBCL). The potential of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, to establish best-in-class efficacy across numerous indications with high unmet needs, including hidradenitis suppurativa (HS). Incyte’s mCALR-targeting molecule (INCA33989) and its potential to be a first-in-class targeted therapy for mCALR positive myelofibrosis (MF) and essential thrombocythemia (ET) patients. The development path for Incyte’s CDK2 inhibitor (INCB123667) and its potential to become a foundational treatment for patients with ovarian cancer. The J.P. Morgan Healthcare Conference presentation and Q&A session can be accessed at investor.incyte.com . A replay will be archived on the Company’s website for 30 days following the presentation. About Niktimvo™ (axatilimab-csfr) Niktimvo (axatilimab-csfr) is a first-in-class anti-CSF-1R antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs). In 2016, Syndax licensed exclusive worldwide rights to develop and commercialize axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in cGVHD and any future indications. Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids are expected to initiate by year end. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256). Niktimvo is a trademark of Incyte. About Tafasitamab (Monjuvi ® ) Tafasitamab (Monjuvi ® ) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb ® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). MorphoSys and Incyte entered into: (a) in January 2020, a collaboration and licensing agreement to develop and commercialize tafasitamab globally; and (b) in February 2024, an agreement whereby Incyte obtained exclusive rights to develop and commercialize tafasitamab globally. In the United States, Monjuvi ® (tafasitamab-cxix) received accelerated approval by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). In Europe, Minjuvi ® (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. XmAb ® is a registered trademark of Xencor, Inc. Monjuvi, Minjuvi, the Minjuvi and Monjuvi logos and the “triangle” design are registered trademarks of Incyte. About Povorcitinib (INCB54707) Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for prurigo nodularis (PN). Phase 2 studies of povorcitinib in PN, asthma and chronic spontaneous urticaria are also ongoing. About Incyte A global biopharmaceutical company on a mission to Solve On. , Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn , X , Instagram , Facebook , YouTube . Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, Incyte’s potential for commercial growth, clinical progress and achievement of milestones in 2025 and longer term, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, and Incyte’s goal of improving the lives of patients, contain predictions, estimates, and other forward-looking statements. These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by FDA and regulatory agencies outside of the United States; the efficacy or safety of our products; the acceptance of our products in the marketplace; market competition; unexpected variations in the demand for our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products; sales, marketing, manufacturing, and distribution requirements, including our ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended September 30, 2024. We disclaim any intent or obligation to update these forward-looking statements.

临床3期上市批准引进/卖出临床2期临床结果

2024-12-25

·贝壳社

进击百亿大蓝海--“容颜杀手”

▲点击图片，了解详情医曜/青栎白癜风，一个困扰1.2亿人的“容颜杀手”。传奇巨星迈克尔・杰克逊用独特的舞台风格和无与伦比的音乐才华，征服了亿万歌迷。然而，其肤色戏剧性转变却成为大众长期争议与误解的焦点。身为黑人的他，皮肤逐渐变白直至近乎全身皆白，彼时，诸多不实传言甚嚣尘上，指责他“背叛种族”，运用所谓“漂白”技术刻意改变肤色，摇身变为“白人”。但真相却是，迈克尔・杰克逊患上了严重“白癜风”，这一疾病早在70年代便缠上了他，致使他无奈只能借助浓妆来极力掩盖皮肤的异样。时至今日，白癜风依旧是医学领域尚未攻克的难题，全球发病率接近2%，仅我国就有近2000万患者。尤其值得关注的是，这种疾病在青少年人群中高发，他们正处于成长关键期，白癜风致使他们在学业、社交、情感等多方面因病症饱受误解歧视，身心健康都遭受严重伤害。无论是患者基数，还是对患者的伤害，攻克白癜风都将带来极大的社会价值。 01 解构白癜风白癜风（Vitiligo）是一种因皮肤和毛囊内的黑色素细胞内酪氨酸酶活性降低或消失，而导致黑素颗粒生成减少或消失引起的局部性或泛发性脱色素病变，属于慢性、系统性的常见皮肤病。在临床上，白癜风表现多为局限性或泛发性的皮肤黏膜色素全然脱失，常以一片或几片边界模糊的白色色素脱失斑片率先出现。多数患者无显著自觉症状，然而随着病情推移，形态与大小各异的皮损会逐步扩散。白癜风不痛不痒，不会传染，也不会影响到寿命，但却对患者的容貌造成了巨大影响，堪称“毁容性”皮肤病。如果白癜风病发在暴露部位，很有可能对患者心理健康造成巨大的影响。据美国皮肤病学会披露，白癜风患者患抑郁症概率高达22%～31%，远高于全球3.1%的平均水平。此外，白癜风患者紫外线防御能力弱，皮肤癌发病率较正常人高，随着患者年龄增加，还容易引发自身免疫并发症。全球白癜风患病率接近2%，据估算全球白癜风患者人数高达1.2亿，其中我国白癜风患者人数近2000万人，且近年来患病率呈逐渐上升的趋势。白癜风的发病没有性别差异，任何年龄均可见，但多数发病于20岁之前的青少年时期，以我国为例，63.4%的患者是年龄小于20岁的青少年。尽管患者有强烈的治疗意愿，但至今还没有一种确定的治疗方法可以彻底治愈白癜风，主要原因是白癜风的病因尚不明确。现代研究表明，白癜风发病机制错综复杂，涵盖自身免疫学说、氧化应激学说、遗传学说等。在这些假说中，自身免疫学说是近年来的研究焦点，该学说指出白癜风由机体内 CD8+T 细胞对黑素细胞的杀伤所致。T淋巴细胞，尤其是细胞毒性CD8+T细胞会渗入皮肤的表皮与真皮交界处，持续侵袭健康区域的黑色素细胞，致使脱色区域持续扩大。图：白癜风免疫回路氧化应激学说则认为黑素细胞内的氧化与抗氧化平衡失调引发了白癜风。在白癜风患者体内，受多种内源性或外源性因素影响，抗氧化酶活性可能降低，或者活性氧生成过多，形成氧化应激状态。这种状态会进一步损害黑素细胞的DNA、蛋白质与脂质等生物大分子，导致黑素细胞凋亡或功能障碍。学习得越多，越感觉到知识的匮乏。随着越来越多研究的展开，单一学说已经很难诠释黑素细胞减少或消失的全貌，更多学者倾向于认为白癜风是多种因素协同作用的结果。其中，氧化应激是关键的起始因素，它介导黑素细胞内在损伤，激活皮肤局部固有免疫反应，同时诱导角质形成细胞趋化因子、细胞因子释放，进而启动针对黑素细胞的特异性T细胞免疫应答，是导致白癜风发病的关键机制。 02 百亿大蓝海鉴于白癜风复杂的致病机制，当前治疗手段十分有限。传统治疗主要包括外用药物（如糖皮质激素、免疫调节剂等）、系统用药（如糖皮质激素、抗氧化剂等）、光疗、手术治疗（如自体表皮移植、黑素细胞移植）等，但都难以达到理想效果。外用糖皮质激素如卤米松乳膏、糠酸莫米松乳膏等，虽适用于早期局限型白癜风，能在白癜风治疗中发挥抗炎、免疫抑制与抗增殖功效，抑制自身免疫对黑素细胞的破坏，为黑素细胞生存与功能恢复助力。但却不能长期使用，否则会引发皮肤萎缩、毛细血管扩张等不良反应。系统应用糖皮质激素如泼尼松，可用于泛发型进展期白癜风，却伴有骨质疏松、高血压、糖尿病等一系列副作用。钙调神经磷酸酶抑制剂如他克莫司软膏、吡美莫司乳膏等，能抑制T淋巴细胞的活化和细胞因子的产生，从而减轻自身免疫对黑素细胞的攻击。它还可以调节皮肤局部的免疫微环境，促进黑素细胞的功能恢复和黑素合成。这类药物没有糖皮质激素导致皮肤萎缩等副作用，但仍可引起或加重局部感染如毛囊炎、痤疮等问题。维生素D3衍生物如卡泊三醇软膏、他西醇软膏等，可以调节皮肤局部的免疫反应，还可以诱导黑素细胞的酪氨酸酶活性增加，促进黑素的合成。但需要与其他药物联合使用，单独使用起效时间太长，需要持续使用数周甚至数月才能看到一定的治疗效果。值得注意的是，上述药物虽被多国地区白癜风诊疗指南收录，却均未获批白癜风适应症。目前全球仅有一款生物制剂获批白癜风适应症，就是芦可替尼乳膏。芦可替尼乳膏由Incyte研发，为局部外用JAK抑制剂，于2022年7月获FDA批准上市，用于12岁及以上非节段型白癜风患者的局部治疗。两项关键III期临床试验结果显示，在第24周，芦可替尼组29.9%的患者面部白癜风严重指数相对基线改善≥75%（F-VASI75），而安慰剂组这一比例为7.5%（TRuE-V1）和12.9%（TRuE-V2）。此外，在治疗第52周时，芦可替尼组约50%的患者达到了F-VASI75。图：芦可替尼乳膏III期临床试验结果，来源：公司公告 2022年12月，康哲药业宣布引进芦可替尼乳膏在中国大陆、港澳台及东南亚十一国的独家开发和商业化权益。2024年9月24日，芦可替尼乳膏白癜风适应症新药上市许可申请（NDA）获得中国国家药品监督管理局受理，此前已在海南省获批临床急需进口并于澳门成功上市。白癜风治愈困难，患者用药周期长且复发率高，市场潜力巨大。虽然芦可替尼是唯一获批白癜风适应症的药物，但其现阶段营收占比却很少，并没有满足这个市场的全部需求。获批白癜风适应症后，芦可替尼销售额从2021年的0.05亿美元激增至2022年的1.29亿美元，2023年销售收入更是进一步攀升至3.38亿美元，同比增长162%。尽管增速很快，但整体规模依然较为有限。综合来看，白癜风目前在医学领域依旧处于一种亟待突破的状态，存在着极为显著且庞大的未被满足的临床需求，新药研发具有广阔的市场前景。 03 JAK抑制剂是最优解？近年来，医学界一直在努力寻找治疗白癜风的有效方法，各大创新药企也纷纷布局。据不完全统计，全球现已有超 20 个白癜风在研管线，其探索靶点主要聚焦于 JAK 抑制剂、PDE4 抑制剂以及白介素抑制剂等方向。这其中，JAK抑制剂无疑成为研发焦点。在白癜风的病理过程中，产生IFN-γ的细胞毒性CD8+T细胞激活JAK，触发其磷酸化，并进一步激活STAT，从而影响基因表达，导致黑素细胞受损。JAK抑制剂能够抑制JAK激酶的活性，截断细胞因子所介导的JAK-STAT信号通路过度激活。当用于白癜风患者皮肤时，可有效削减如IFN-γ、白细胞介素-15（IL-15）等炎症细胞因子的信号传导，使得皮肤病变区域的CD8+T细胞数量显著减少，从而极大减轻对黑素细胞的免疫侵袭。已经获批的芦可替尼乳膏，就是FDA批准的首个也是唯一一个局部外用JAK抑制剂。目前白癜风在研管线中，进度较快的几乎都涉及JAK靶点。图：白癜风在研管线，来源：西南证券利特昔替尼是辉瑞研发的新型口服JAK3抑制剂，目前白癜风适应症在美国已进入III期临床，是除芦可替尼乳膏外全球进展最快的白癜风在研新药。IIb期研究中，发现每天服用一次50mg片剂可显著改善面部白癜风病变比例（与安慰剂相比，利特昔替尼组F-VASI在24周时降低高达75%）。 Povorcitinib是Incyte研发的口服JAK1抑制小分子药物，目前正在海外若干国家进行非节段型白癜风和HS的III期临床试验。IIb期临床研究结果显示，治疗24周，与安慰剂相比，接受每日一次Povorcitinib治疗的患者的全身皮损显著复色。今年4月，康哲药业获得了Povorcitinib在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一国研究、开发、注册及商业化产品的独家许可权利。艾玛昔替尼是恒瑞医药自主研发的首个国产JAK1抑制剂，适应症包括特异性皮炎、溃疡性结肠炎、斑秃、强直性脊柱炎、白癜风等。2020年12月，恒瑞在国内启动了艾玛昔替尼碱软膏用于治疗白癜风的II/III期临床，是国内进度最快的白癜风在研新药。此外，泰恩康旗下王宏林教授团队研发的赛克乳香酸（CKBA）独辟蹊径，通过靶向ACC1和MFE2调控细胞脂代谢，以此抑制CD8+T细胞产生效应分子与发挥效应功能。目前CKBA 软膏正全力推进白癜风适应II期临床试验工作，有望成为同类别中首创的药物分子，为白癜风治疗带来全新思路。除靶向药物研发这一主线外，近年来干细胞治疗技术蓬勃兴起，在众多系统疾病与皮肤疾病治疗中大放异彩，也为白癜风治疗开拓出崭新路径。上海复旦大学等联合团队匠心独运，成功开发出自体培养上皮移植（ACEG）技术。临床数据显示，ACEG细胞疗法在726 名患者中的总有效率高达82.81%，与传统手术仅52.69%的有效率相比，优势尽显。由于白癜风致病机制复杂，目前的创新药想要彻底治愈白癜风还存在一定的距离，但随着细胞治疗与再生医学的快速发展，使用干细胞治疗以及基因治疗理论上可以从根本上治愈白癜风。从整体来看，医学界已经在白癜风领域深度布局多年，且已获得显著进展，越来越多的靶向药物出现为白癜风治疗开启了新篇章。随着未来越来越多白癜风药物的上市，这一世纪难题被攻克或仅是一个时间问题。往期推荐 1 2024年了，为什么“痛经”还是没药可用 2 国产「十亿美元分子」并不遥远 _ 3 破局！国内首款CD19 ADC药物获批上市 _ *声明：本稿件为转载，仅用于分享，不代表本公众号立场，如涉及版权等问题，请尽快联系我们，我们将第一时间更正或删除，谢谢！投稿请添加小助手：bioclub666

100 项与 Povorcitinib 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结节性痒疹	临床3期	美国	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	日本	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	阿根廷	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	澳大利亚	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	奥地利	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	比利时	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	保加利亚	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	加拿大	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	智利	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	捷克	Incyte Corp.	2024-10-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05061693 (CTgov)	临床2期	结节性痒疹	146	placebo (Placebo)	顧網顧窪構遞選夢衊餘(繭醖憲築選壓顧鹹構構) = 壓繭製選餘鏇獵醖窪獵積鹹鏇襯築糧蓋憲鹽築 (鑰製築製廠醖鏇構獵憲, 蓋壓窪簾壓願廠顧壓築 ~ 獵醖膚繭構蓋選積積簾) 更多	-	2024-08-27
				Povorcitinib (Povorcitinib 15 mg)	顧網顧窪構遞選夢衊餘(繭醖憲築選壓顧鹹構構) = 鹹鬱鬱壓築襯簾遞鹹餘積鹹鏇襯築糧蓋憲鹽築 (鑰製築製廠醖鏇構獵憲, 製積觸衊簾夢顧艱憲簾 ~ 網觸鬱壓淵選糧蓋鑰襯) 更多
NCT05061693 (Corporate Publications) 人工标引	临床2期	结节性痒疹	146	Povorcitinib 15 mg	糧構鹹廠構築廠獵壓積(鹽鬱積鹽鏇構淵齋鏇餘) = 窪鹹選壓觸選繭網繭憲鏇餘簾餘艱築憲範憲鹹 (廠衊觸築獵憲鏇顧窪醖 ) 达到更多	积极	2024-03-10
				Povorcitinib 45 mg	糧構鹹廠構築廠獵壓積(鹽鬱積鹽鏇構淵齋鏇餘) = 憲淵壓艱鬱醖廠鹹膚襯鏇餘簾餘艱築憲範憲鹹 (廠衊觸築獵憲鏇顧窪醖 ) 达到更多
NCT04818346 (AAD2024) 人工标引	临床2期	-	171	Povorcitinib (age≤40 years)	齋鏇製鹹簾膚願夢醖積(蓋選淵網壓構願構艱夢) = 鏇鏇壓鏇鏇製鏇襯構廠觸艱窪遞廠鏇夢選艱鏇 (鏇鑰糧鏇鹹醖構顧醖鏇 )	积极	2024-03-10
				Povorcitinib (age>40 years)	齋鏇製鹹簾膚願夢醖積(蓋選淵網壓構願構艱夢) = 積範積鑰鹹鹹鏇觸觸壓觸艱窪遞廠鏇夢選艱鏇 (鏇鑰糧鏇鹹醖構顧醖鏇 )
NCT04818346 (Corporate Publications) 人工标引	临床2期	非节段型白癜风	171	povorcitinib15-to-75 mg	網鹽製窪築膚獵繭鬱鏇(簾鹽鹹網鹽壓選夢憲壓) = 壓獵鏇範鬱夢願構艱積鏇膚願衊構夢膚築構餘 (醖憲築鹽廠夢夢顧憲選 ) 更多	积极	2023-10-11
				povorcitinib45 mg	網鹽製窪築膚獵繭鬱鏇(簾鹽鹹網鹽壓選夢憲壓) = 觸淵範憲積選膚鹹獵憲鏇膚願衊構夢膚築構餘 (醖憲築鹽廠夢夢顧憲選 ) 更多
NCT04818346 (phase 2b, EADV2023)	临床2期	白癜风 Fitzpatrick skin types I - III	171	Povorcitinib 15 mg	簾構齋醖製願鹽憲壓選(顧積願窪選鑰遞糧膚願) = 繭繭獵範獵艱獵鹽壓觸餘構夢積餘築築壓衊鏇 (夢築憲憲獵選鬱觸繭顧 )	积极	2023-10-11
				Povorcitinib 45 mg	簾構齋醖製願鹽憲壓選(顧積願窪選鑰遞糧膚願) = 衊鬱鏇簾繭壓衊廠窪糧餘構夢積餘築築壓衊鏇 (夢築憲憲獵選鬱觸繭顧 )
EADV2023	临床2期	-	209	Povorcitinib 15 mg	繭襯憲顧淵鹽糧窪廠築(壓醖窪壓製夢鑰襯夢鬱) = 膚鑰膚壓糧鬱窪繭鏇衊廠觸襯鹽壓選餘齋鹹鏇 (憲繭選選餘遞積築簾觸 )	-	2023-10-11
				Povorcitinib 45 mg	繭襯憲顧淵鹽糧窪廠築(壓醖窪壓製夢鑰襯夢鬱) = 遞衊觸淵淵壓膚廠範齋廠觸襯鹽壓選餘齋鹹鏇 (憲繭選選餘遞積築簾觸 )
NCT04476043 (phase 2 study, EHSF2023)	临床2期	化脓性汗腺炎	174	Povorcitinib 15 mg	糧範選壓衊夢廠糧遞製(廠餘願壓衊簾壓觸醖醖) = 11.5% 壓憲顧廠鹹獵淵構蓋鑰 (襯鹹獵遞衊窪艱齋願醖 ) 更多	积极	2023-09-27
				Povorcitinib 45 mg
NCT04818346 (phase 2b, CTgov)	临床2期	非节段型白癜风	171	placebo+povorcitinib (Placebo)	鑰鹹顧鑰選獵鏇製範鏇(齋壓鬱網築觸淵築築鑰) = 繭積觸觸夢繭構鏇選簾齋憲廠鹹顧餘積選繭選 (窪鹹膚製艱鏇憲製餘範, 鹹壓觸鏇簾餘淵鏇繭夢 ~ 憲繭餘壓範構範鏇構齋) 更多	-	2023-07-05
				Povorcitinib (Povorcitinib 15 mg)	鑰鹹顧鑰選獵鏇製範鏇(齋壓鬱網築觸淵築築鑰) = 餘壓鏇壓選壓蓋繭積製齋憲廠鹹顧餘積選繭選 (窪鹹膚製艱鏇憲製餘範, 鹽餘鹽壓膚遞淵淵鬱壓 ~ 觸齋鹽顧夢夢遞獵觸鏇) 更多
NCT04476043 (phase 2 dose-ranging study \| phase 2 study, CTgov)	临床2期	化脓性汗腺炎	209	INCB054707 (INCB054707 15 mg)	淵膚範衊積襯繭壓繭繭(繭膚顧積簾鏇壓艱窪積) = 鹽餘壓醖顧觸網蓋遞鏇艱憲艱顧窪蓋蓋鏇鑰糧 (網鹽憲膚選鏇獵淵壓艱, 淵鹹廠衊簾鑰襯糧壓觸 ~ 鑰糧鹽鏇鬱壓淵衊憲廠) 更多	-	2023-01-26
				INCB054707 (INCB054707 45 mg)	淵膚範衊積襯繭壓繭繭(繭膚顧積簾鏇壓艱窪積) = 選願醖憲餘構鑰夢糧築艱憲艱顧窪蓋蓋鏇鑰糧 (網鹽憲膚選鏇獵淵壓艱, 簾鑰蓋餘觸衊衊淵願遞 ~ 壓膚淵選製顧齋觸齋構) 更多
NCT04476043 (phase 2 dose-ranging study, EADV2022)	临床2期	化脓性汗腺炎	209	INCB054707 15 mg	獵廠觸鹽蓋遞蓋糧廠積(廠齋憲廠壓鏇蓋壓鹽築) = 鬱艱膚壓艱鑰淵範鏇築鹽餘願鑰顧衊範壓觸鹽 (夢衊簾積窪願蓋選網壓 ) 更多	积极	2022-09-07
				INCB054707 45 mg	獵廠觸鹽蓋遞蓋糧廠積(廠齋憲廠壓鏇蓋壓鹽築) = 廠鑰艱簾艱製顧簾糧壓鹽餘願鑰顧衊範壓觸鹽 (夢衊簾積窪願蓋選網壓 ) 更多